Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Children with Severe Systemic Juvenile Idiopathic Arthritis: 12-month Follow-up
https://doi.org/10.15690/vsp.v12i2.617
Abstract
Aim: to carry out a retrospective analysis of efficacy and safety of tocilizumab treatment in children with severe resistant forms of systemic juvenile idiopathic arthritis. Patients and methods: 75 patients (35 girls and 40 boys) aged 8,8 (6; 12) years old with severe systemic juvenile idiopathic arthritis resistant to routine immunosuppressive therapy were included to the study. The mean duration of the disease before tocilizumab administration was 3,2 (1,9; 5,2) years. The diagnose was made based on the ILAR criteria. All patients were performed standard clinical and laboratory examination. The efficacy of treatment was assessed according to the pediatric criteria for improvement of the American College of Rheumatology. The frequency of achievement of non-active stage and medicinal remission of the disease were considered to be the target characteristics of the treatment efficacy. Results: in 6 months of treatment non-active stage of the disease was recorded in 64% of patients, in 12 months — in 73% of patients. Undesirable effects were represented by mild and moderate infections as well as changes in certain laboratory indexes: leucopenia, granulocytopenia, increased transaminase activity. Conclusions: tocilizumab is a highly effective drug in treatment of patients with the most severe systemic form of juvenile arthritis resistant to steroids, methotrexate, cyclosporine, as well as combined immunosuppressive therapy and anti-TNF and anti-B cell therapy.
About the Authors
A. A. Baranov
Scientific Centre of Children Health, RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
E. I. Alexeeva
Scientific Centre of Children Health, RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Contacts: Alekseyeva Yekaterina Iosifovna, PhD, MD, professor, Head of Rheumatological Department, National Center of Children’s Health, Russian Academy of Medical Sciences, Dean of Pediatric Faculty, I.M. Sechenov First Moscow State Medical University Address: 119991, Moscow, Lomonosovskiy Prospect, 2, bldg. 1, Tel.: (499) 134-02-97, e-mail: alekatya@yandex.ru
Russian Federation
Contacts: Alekseyeva Yekaterina Iosifovna, PhD, MD, professor, Head of Rheumatological Department, National Center of Children’s Health, Russian Academy of Medical Sciences, Dean of Pediatric Faculty, I.M. Sechenov First Moscow State Medical University Address: 119991, Moscow, Lomonosovskiy Prospect, 2, bldg. 1, Tel.: (499) 134-02-97, e-mail: alekatya@yandex.ru
R. V. Denisova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
S. I. Valieva
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
T. M. Bzarova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
K. B. Isaeva
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
T. V. Steptsova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. V. Mitenko
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
E. G. Chistyakova
Scientific Centre of Children Health, RAMS, Moscow;
I.M. Sechenov First Moscow State Medical University
Russian Federation
Russian Federation
A. N. Fetisova
Scientific Centre of Children Health, RAMS, Moscow
Russian Federation
Russian Federation
References
1. Petty R. E., Southwood T. R., Manners P. et al. International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001. J. Rheumatol. 2004; 31: 390–392.
2. Lomater C., Gerloni V., Gattinara M., Mazzotti J., Cimaz R., Fantini F. Systemic onset juvenile idiopathic arthritis: a retrospective study of 80 consecutive patients followed for 10 years. J. Rheumatol. 2000; 27: 491–496.
3. Ravelli A., Martini A. Juvenile idiopathic arthritis. Lancet. 2007; 369: 767–778.
4. Woo P., Southwood T. R., Prieur A. M. et al. Randomized, placebocontrolled, crossover trial of low-dose oral methotrexate in children with extended oligoarticular or systemic arthritis. Arthritis Rheum. 2000; 43: 1849–1857.
5. De Benedetti F., Martini A. Is systemic juvenile rheumatoid arthritis an interleu-kin 6 mediated disease? J. Rheumatol. 1998; 25: 203–207.
6. De Benedetti F., Massa M., Robbioni P., Ravelli A., Burgio G. R., Martini A. Correlation of serum interleukin-6 levels with joint involvement and thrombocytosis in systemic juvenile rheumatoid arthritis. Arthritis Rheum. 1991; 34: 1158–1163.
7. De Benedetti F., Pignatti P., Gerloni V. et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. J. Rheumatol. 1997; 24: 1403–1409.
8. De Benedetti F., Alonzi T., Moretta A. et al. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulinlike growth factor-I: a model for stunted growth in children with chronic inflammation. J. Clin. Invest. 1997; 99: 643–650.
9. De Benedetti F., Rucci N., Del Fattore A. et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum. 2006; 54: 3551–3563.
10. Cazzola M., Ponchio L., De Benedetti F. et al. Defective iron supply for erythropoiesis and adequate endogenous erythropoietin production in the anemia associated with systemic-onset juvenile chronic arthritis. Blood. 1996; 87: 4824–4830.
11. Schoels M. M., van der Heijde D., Breedveld F. C. et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann. Rheum. Dis. 2013; 72 (4): 583–589.
12. Horneff G., De Bock F., Foeldvari I. et al. Safety and efficacy of combination of etanercept and methotrexate compared to treatment with etanercept only in patients with juvenile idiopathic arthritis (JIA): preliminary data from the German JIA Registry. Ann. Rheum. Dis. 2009; 68: 519–525.
13. Prince F. H., Twilt M., ten Cate R. et al. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register. Ann. Rheum. Dis. 2009; 68: 635–641.
14. Yokota S., Imagawa T., Miyamae T. Safety and efficacy of up to three years of continuous tocilizumab therapy in children with systemic-onset juvenile idiopathic arthritis [SAT0536]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 715.
15. Inaba Y., Aoki C., Ozawa R. Radiologic evaluation of large joints during tocilizumab treatment in children with systemic juvenile idiopathic arthritis [SAT0555]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 720.
16. Yokota S., Imagawa T., Mori M. et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomized, double-blind, placebo-controlled, withdrawal phase III trial. Lancet. 2008; 371: 998–1006.
17. Yokota S., Miyamae T., Imagawa T. et al. Therapeutic efficacy of humanized recombinant anti-interleukin-6 receptor antibody in children with systemic-onset juvenile idiopathic arthritis. Arthritis Rheum. 2005; 52: 818–825.
18. Kaneko U., Imagawa T., Kishi T. Discrepancy between pro gression of joint damage and improvement of systemic inflammation in patients with systemic-onset juvenile idiopathic arthritis treated with tocilizumab [SAT0548]. Ann. Rheum. Dis. 2009; 68 (Suppl. 3): 719.
19. De Benedetti F., Brunner H. I., Ruperto N., Kenwright A. et al. Randomized trial of tocilizumab in systemic juvenile idiopathic arthritis. N. Engl. J. Med. 2012; 367 (25): 2385–2395.
20. Yokota S., Tanaka T., Kishimot T. Efficacy, safety and tolerability of tocilizumab in patients with systemic juvenile idiopathic arthritis. Ther. Adv. Musculoskelet Dis. 2012; 4 (6): 387–397.
21. Russo R., Katsicas M. Tocilizumab in jia patients who have inadequate response to anti-tumour necrosis factor therapy. Pediatr. Rheumatol. Online J. 2011; 9 (Suppl. 1): 186.
22. Sawhney S., Aggarwal M. Tocilizumab for the treatment of systemic onset JIA: a single centre experience from India. Pediatr. Rheumatol. Online J. 2012; 10 (Suppl. 1): 49. REFERENCES 34
23. Smolen J. S., Schoels M. M., Nishimoto N. Consensus state ment on blocking the effects of interleukin-6 and in particular by interleuki n-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Ann. Rheum. Dis. 2013; 72 (4): 482–492.
24. Alexeeva E., Denisova R., Valieva S., Bzarova T., Isayeva K., Sleptsova T., Mitenko E. Safety and efficacy of tocilizumab treatment in children with systemic onset of juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 2011; 9 (Suppl. 1): 202.
25. Schiff M. H., Kremer J. M., Jahreis A., Vernon E., Isaacs J. D., van Vollenhoven R. F. Integrated safety in tocilizumab clinical trials. Arthritis Res. Ther. 2011; 13 (5): 141.
26. Davi S., Lattanzi B., Rosina S. et al. Sensitivity and specificity of current diagnostic guidelines in children with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis. Pediatr. Rheumatol. Online J. 2011; 9 (Suppl. 1): 101.
Review
For citations:
Baranov A.A., Alexeeva E.I., Denisova R.V., Valieva S.I., Bzarova T.M., Isaeva K.B., Steptsova T.V., Mitenko E.V., Chistyakova E.G., Fetisova A.N. Retrospective Analysis of Efficacy and Safety of Tocilizumab Treatment in Children with Severe Systemic Juvenile Idiopathic Arthritis: 12-month Follow-up. Current Pediatrics. 2013;12(2):26-34. (In Russ.) https://doi.org/10.15690/vsp.v12i2.617
Views:
802
Email this article 
